The manufacturing function at Cellmid Limited

Cellmid has recently completed humanisation of its first-in-class oncology antibody targeting midkine, an embryonic cytokine. As a first molecule against this novel target, our key consideration has been to take our drug to the clinic at the earliest while reducing the costs, as well as technical and development risks associated with such a novel program. One of the largest cost components of our program is manufacturing hence we have done extensive research on potential manufacturers and their capabilities.